Molecular mechanisms and therapeutic implications of the sympathetic nervous system in bone-related disorders: a brain-bone axis perspective

Abstract

The global aging crisis has increased the prevalence of skeletal disorders, necessitating innovative therapeutic strategies. This review employs the brain-bone axis (BBA) framework to examine the role of the sympathetic nervous system (SNS) in bone metabolism. The research systematically elucidates the molecular mechanisms by which the SNS mediates signaling pathways through neurofibers and neurotransmitters, such as norepinephrine, dopamine, neuropeptide Y, and leptin, regulating interactions between bone-related cells to maintain skeletal homeostasis. It also identifies the pathological associations between the dysregulation of these pathways and the progression of bone-related conditions, such as osteoporosis, osteoarthritis, and intervertebral disc degeneration. By integrating current evidence, we identify novel therapeutic targets within the BBA and propose neuro-centric intervention strategies to mitigate skeletal diseases. This review deepens the understanding of neuro-skeletal interactions and lays a foundation for innovative treatments for bone-related pathologies.

References

[1] Wen ZQ, et al. . Insights into the underlying pathogenesis and therapeutic potential of endoplasmic reticulum stress in degenerative musculoskeletal diseases. Mil. Med. Res., 2023, 10: 54

[2] Global, regional, and national burden of osteoarthritis. 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Rheumatol., 2023, 5: e508-e522.

[3] Yeh EJ, Gitlin M, Sorio F, Mccloskey E. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among postmenopausal women across eight European countries. Arch. Osteoporos., 2023, 1868

[4] Jiang YL, et al. . The protective effects of osteocyte-derived extracellular vesicles against alzheimer’s disease diminished with aging. Adv. Sci., 2022, 9e2105316

[5] Zhao Y, et al. . Inspiration for the prevention and treatment of neuropsychiatric disorders: new Insight from the bone-brain-axis. Brain Res Bull., 2021, 177: 263-272.

[6] Fukuda T, et al. . Sema3a regulates bone-mass accrual through sensory innervations. Nature, 2013, 497: 490-493.

[7] Chamouni A, Schreiweis C, Oury F. Bone, brain & beyond. Rev. Endocr. Metab. Disord., 2015, 16: 99-113.

[8] Liu T, Wu H, Li J, Zhu C, Wei J. Unraveling the bone-brain axis: a new frontier in parkinson's disease research. Int. J. Mol. Sci., 2024, 25: 12842

[9] Zhang F, Zhang W. Research progress in alzheimer’s disease and bone-brain axis. Ageing Res. Rev., 2024, 98102341

[10] Cheng X, Lowin T, Honke N, Pongratz G. Components of the sympathetic nervous system as targets to modulate inflammation - rheumatoid arthritis synovial fibroblasts as neuron-like cells?. J. Inflamm., 2023, 20: 9

[11] Zhang W, et al. . The role of sympathetic nerves in osteoporosis: a narrative review. Biomedicines, 2022, 11: 33

[12] Farmer DGS, et al. . On the presence and functional significance of sympathetic premotor neurons with collateralized spinal axons in the rat. J. Physiol., 2019, 597: 3407-3423.

[13] Tsentsevitsky A, Nurullin L, Tyapkina O, Bukharaeva E. Sympathomimetics regulate quantal acetylcholine release at neuromuscular junctions through various types of adrenoreceptors. Mol. Cell Neurosci., 2020, 108103550

[14] Li J, et al. . Emerging roles of nerve-bone axis in modulating skeletal system. Med. Res. Rev., 2024, 44: 1867-1903.

[15] Wan QQ, et al. . Crosstalk between bone and nerves within bone. Adv. Sci., 2021, 82003390

[16] Shi H, Chen M. The brain-bone axis: unraveling the complex interplay between the central nervous system and skeletal metabolism. Eur. J. Med. Res., 2024, 29317

[17] He JY, Jiang LS, Dai LY. The roles of the sympathetic nervous system in osteoporotic diseases: a review of experimental and clinical studies. Ageing Res. Rev., 2011, 10: 253-263.

[18] Sohn R, et al. . Osteoarthritis patients exhibit an autonomic dysfunction with indirect sympathetic dominance. J. Transl. Med., 2024, 22467

[19] Du Y, Zhang L, Wang Z, Zhao X, Zou J. Endocrine regulation of extra-skeletal organs by bone-derived secreted protein and the effect of mechanical stimulation. Front. Cell Dev. Biol., 2021, 9778015

[20] He T, et al. . Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs. Bone Res., 2025, 13: 49

[21] Thai J, Kyloh M, Travis L, Spencer NJ, Ivanusic JJ. Identifying spinal afferent (sensory) nerve endings that innervate the marrow cavity and periosteum using anterograde tracing. J. Comp. Neurol., 2020, 528: 1903-1916.

[22] Hohmann EL, Elde RP, Rysavy JA, Einzig S, Gebhard RL. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science, 1986, 232: 868-871.

[23] Wu C, Sun Z, He C, Sun R. Ph-dependent osteoimmunomodulation: molecular mechanisms and therapeutic targeting in bone disorders. Pharm. Res., 2025, 218107838

[24] Yi S, et al. . Bone remodeling: histone modifications as fate determinants of bone cell differentiation. Int. J. Mol. Sci., 2019, 20: 3147

[25] Martelli D, Brooks VL. Leptin increases: physiological roles in the control of sympathetic nerve activity, energy balance, and the hypothalamic-pituitary-thyroid axis. Int. J. Mol. Sci., 2023, 24: 2684

[26] Zhao Y, et al. . Crosstalk between the neuroendocrine system and bone homeostasis. Endocr. Rev., 2024, 45: 95-124.

[27] Xie W, Li F, Han Y, Li Z, Xiao J. Neuropeptides are associated with pain threshold and bone microstructure in ovariectomized rats. Neuropeptides, 2020, 81101995

[28] Chen Y, Guo B, Ma G, Cao H. Sensory nerve regulation of bone homeostasis: emerging therapeutic opportunities for bone-related diseases. Ageing Res. Rev., 2024, 99102372

[29] Ma C, et al. . Autonomic neural regulation in mediating the brain-bone axis: mechanisms and Implications for regeneration under psychological stress. QJM, 2024, 117: 95-108.

[30] Gadomski S, et al. . A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise. Cell Stem. Cell., 2022, 29: 528-544.

[31] Guo Q, et al. . Sympathetic innervation regulates osteocyte-mediated cortical bone resorption during lactation. Adv. Sci., 2023, 10e2207602

[32] Xiao Y, et al. . Interoceptive regulation of skeletal tissue homeostasis and repair. Bone Res., 2023, 11: 48

[33] Elefteriou F. Impact of the autonomic nervous system on the skeleton. Physiol. Rev., 2018, 98: 1083-1112.

[34] Chen Y, et al. . Sympathetic cholinergic nerve fibres promote BMSCs differentiation into osteoblasts via NRNT secretion: a potential treatment for osteoporosis. J. Orthop. Surg. Res., 2025, 20: 571

[35] Lu W, et al. . Dopamine delays articular cartilage degradation in osteoarthritis by negative regulation of the NF-kappaB and Jak2/Stat3 signaling pathways. Biomed. Pharmacother., 2019, 119109419

[36] Kang X, et al. . Neuropeptide y acts directly on cartilage homeostasis and exacerbates progression of osteoarthritis through NPY2R. J. Bone Miner. Res., 2020, 35: 1375-1384.

[37] Fernandois D, et al. . Multi-organ increase in norepinephrine levels after central leptin administration and diet-induced obesity. Int. J. Mol. Sci., 2023, 24: 16909

[38] Hou Y, et al. . Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of parkinson’s disease. Microbiome, 2021, 934

[39] Guo X, et al. . Osteocalcin ameliorates motor dysfunction in a 6-hydroxydopamine-induced parkinson’s disease rat model through AKT/gsk3beta signaling. Front. Mol. Neurosci., 2018, 11: 343

[40] Kim B, et al. . Pathogenic upregulation of glial lipocalin-2 in the Parkinsonian dopaminergic system. J. Neurosci., 2016, 36: 5608-5622.

[41] Han H, et al. . Macrophage-derived osteopontin (spp1) protects from nonalcoholic steatohepatitis. Gastroenterology, 2023, 165: 201-217.

[42] Melero-Jerez C, et al. . Myeloid-derived suppressor cells support remyelination in a murine model of multiple sclerosis by promoting oligodendrocyte precursor cell survival, proliferation, and differentiation. Glia, 2021, 69: 905-924.

[43] Marrella A, et al. . Engineering vascularized and innervated bone biomaterials for improved skeletal tissue regeneration. Mater. Today, 2018, 21: 362-376.

[44] Rosch G, et al. . Sympathectomy aggravates subchondral bone changes during osteoarthritis progression in mice without affecting cartilage degeneration or synovial inflammation. Osteoarthr. Cartil., 2022, 30: 461-474.

[45] Bajayo A, et al. . Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc. Natl. Acad. Sci. USA, 2012, 109: 15455-15460.

[46] Espinosa-Medina I, et al. . The sacral autonomic outflow is sympathetic. Science, 2016, 354: 893-897.

[47] Garcia-Garcia A, et al. . Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes. Blood, 2019, 133: 224-236.

[48] Fielding C, et al. . Cholinergic signals preserve haematopoietic stem cell quiescence during regenerative haematopoiesis. Nat. Commun., 2022, 13543

[49] Asada N, et al. . Matrix-embedded osteocytes regulate mobilization of hematopoietic stem/progenitor cells. Cell Stem Cell, 2013, 12: 737-747.

[50] Shi Y, et al. . Signaling through the m(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab., 2010, 11: 231-238.

[51] Zoccali C, et al. . The autonomic nervous system and bone health in chronic kidney disease. Eur. J. Clin. Invest., 2025, 55: e70007

[52] Zhong XP, Xia WF. Regulation of bone metabolism mediated by beta-adrenergic receptor and its clinical application. World J. Clin. Cases, 2021, 9: 8967-8973.

[53] Yarahmadi HB, et al. . Study of the biological relevance of wnt/β-catenin signaling pathway and β-adrenergic regulation in osteoblastic differentiation of mesenchymal stem cells. Gene Rep., 2022, 29101662

[54] Xiao Y, et al. . Advances in the roles of ATF4 in osteoporosis. Biomed. Pharmacother., 2023, 169115864

[55] Liang H, et al. . Selective beta2-adrenoreceptor signaling regulates osteoclastogenesis via modulating RANKL production and neuropeptides expression in osteocytic mlo-y4 cells. J. Cell Biochem., 2019, 120: 7238-7247.

[56] Hwang HS, Lee MH, Go DJ, Kim HA. Norepinephrine modulates IL-1beta-induced catabolic response of human chondrocytes. BMC Musculoskelet. Disord., 2021, 22724

[57] Huang HH, Brennan TC, Muir MM, Mason RS. Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J. Cell Physiol., 2009, 220: 267-275.

[58] Otto E, et al. . Crosstalk of brain and bone-clinical observations and their molecular bases. Int. J. Mol. Sci., 2020, 21: 4946

[59] Lauretani F, et al. . Dopamine pharmacodynamics: new insights. Int. J. Mol. Sci., 2024, 25: 5293

[60] Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control. Cells, 2021, 10: 735

[61] Lee J. Tetrahydrocannabinol and dopamine D1 receptor. Front. Neurosci., 2024, 181360205

[62] Weerasinghe DK, et al. . Antipsychotic-induced bone loss: the role of dopamine, serotonin, and adrenergic receptor signalling. Front. Cell Dev. Biol., 2023, 111184550

[63] Zhu J, et al. . Activation of dopamine receptor D1 promotes osteogenic differentiation and reduces glucocorticoid-induced bone loss by upregulating the erk1/2 signaling pathway. Mol. Med., 2022, 28: 23

[64] Wang L, et al. . Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway. Cell Signal., 2021, 78109847

[65] Feng Y, Lu Y. Immunomodulatory effects of dopamine in inflammatory diseases. Front. Immunol., 2021, 12663102

[66] Marino F, et al. . Dopaminergic inhibition of human neutrophils is exerted through D1-like receptors and affected by bacterial infection. Immunology, 2022, 167: 508-527.

[67] Yan Y, et al. . Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell, 2015, 160: 62-73.

[68] Zhang Y, et al. . Neuronal induction of bone-fat imbalance through osteocyte neuropeptide Y. Adv. Sci., 2021, 8e2100808

[69] Chen QC, Zhang Y. The role of NPY in the regulation of bone metabolism. Front. Endocrinol., 2022, 13833485

[70] Baldock PA, et al. . Neuropeptide Y attenuates stress-induced bone loss through suppression of noradrenaline circuits. J. Bone Miner. Res., 2014, 29: 2238-2249.

[71] Ormanji MS, et al. . Adipose tissue denervation blunted the decrease in bone formation promoted by obesity in rats. Nutrients, 2023, 15: 3574

[72] Qi Y, Fu M, Herzog H. Y2 receptor signalling in NPY neurons controls bone formation and fasting induced feeding but not spontaneous feeding. Neuropeptides, 2016, 55: 91-97.

[73] Lee NJ, et al. . Osteoblast specific Y1 receptor deletion enhances bone mass. Bone, 2011, 48: 461-467.

[74] Seldeen KL, et al. . Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. Neuropeptides, 2018, 67: 45-55.

[75] Perakakis N, Farr OM, Mantzoros CS. Leptin in leanness and obesity: JACC state-of-the-art review. J. Am. Coll. Cardiol., 2021, 77: 745-760.

[76] Zabeau L, et al. . A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions. Cell Mol. Life Sci., 2019, 76: 1201-1214.

[77] Wee N, et al. . Leptin receptor in osteocytes promotes cortical bone consolidation in female mice. J. Endocrinol., 2022, 255: 25-37.

[78] Lin Z, Yu G, Xiong S, Lin Y, Li Z. Leptin and melatonin’s effects on ovx rodents’ bone metabolism. Front. Endocrinol., 2023, 141185476

[79] Wada N, et al. . Leptin and its receptors. J. Chem. Neuroanat., 2014, 61-62: 191-199.

[80] Mohammadi SM, Saniee N, Borzoo T, Radmanesh E. Osteoporosis and leptin: a systematic review. Iran. J. Public Health, 2024, 53: 93-103. DOI:

[81] Liu C, Li X. Role of leptin and adiponectin in immune response and inflammation. Int. Immunopharmacol., 2025, 161115082

[82] Cordero-Barreal A, et al. . An update on the role of leptin in the immuno-metabolism of cartilage. Int. J. Mol. Sci., 2021, 22: 2411

[83] Ensrud KE, Crandall CJ. Osteoporosis. Ann. Intern Med., 2024, 177: ITC1-ITC16.

[84] Yang J, Jiang T, Xu G, Liu W. Bibliometrics analysis and visualization of sarcopenia associated with osteoporosis from 2000 to 2022. J. Pain. Res., 2023, 16: 821-837.

[85] Hsieh CI, et al. . Automated bone mineral density prediction and fracture risk assessment using plain radiographs via deep learning. Nat. Commun., 2021, 125472

[86] Guan Z, et al. . Bone mass loss in chronic heart failure is associated with sympathetic nerve activation. Bone, 2023, 166116596

[87] Wu Y, Zhang Q, Zhao B, Wang X. Effect and mechanism of propranolol on promoting osteogenic differentiation and early implant osseointegration. Int. J. Mol. Med., 2021, 48: 191

[88] Wang Z, et al. . Mechanical loading alleviated the inhibition of beta2-adrenergic receptor agonist terbutaline on bone regeneration. FASEB J., 2021, 35e22033

[89] Sui B, et al. . Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress. Int. J. Oral. Sci., 2022, 14: 39

[90] Lin Q, et al. . Neuropeptides as regulators of bone metabolism: from molecular mechanisms to traditional Chinese medicine intervention strategies. Front. Pharm., 2025, 161516038

[91] Wee NKY, Vrhovac Madunic I, Ivanisevic T, Sinder BP, Kalajzic I. Divergent effects of peripheral and global neuropeptide Y deletion. J. Musculoskelet. Neuronal Interact., 2020, 20: 579-590. DOI:

[92] Xie W, et al. . Neuropeptide Y1 receptor antagonist promotes osteoporosis and microdamage repair and enhances osteogenic differentiation of bone marrow stem cells via cAMP/PKA/CREB pathway. Aging, 2020, 12: 8120-8136.

[93] Dong P, et al. . Melatonin induces osteoblastic differentiation of mesenchymal stem cells and promotes fracture healing in a rat model of femoral fracture via neuropeptide y/neuropeptide Y receptor Y1 signaling. Pharmacology, 2018, 102: 272-280.

[94] Elefteriou F, et al. . Leptin regulation of bone resorption by the sympathetic nervous system and cart. Nature, 2005, 434: 514-520.

[95] Reid IR, Baldock PA, Cornish J. Effects of leptin on the skeleton. Endocr. Rev., 2018, 39: 938-959.

[96] Ahmed HH, Morcos NY, Eskander EF, Seoudi DM, Shalby AB. Potential role of leptin against glucocorticoid-induced secondary osteoporosis in adult female rats. Eur. Rev. Med. Pharm. Sci., 2012, 16: 1446-1452. DOI:

[97] Sun P, et al. . Effect of qing’e decoction on leptin/leptin receptor and bone metabolism in naturally aging rats. Evid. Based Complement Altern. Med., 2020, 20202532081

[98] Chen S, et al. . Kindlin-2 inhibits NLRP3 inflammasome activation in nucleus pulposus to maintain homeostasis of the intervertebral disc. Bone Res., 2022, 10: 5

[99] Yao Q, et al. . Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal. Transduct. Target Ther., 2023, 8: 56

[100] Berenbaum F, Walker C. Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. Postgrad. Med., 2020, 132: 377-384.

[101] Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med. Clin. North Am., 2020, 104: 293-311.

[102] Martel-Pelletier J, et al. . Osteoarthritis. Nat. Rev. Dis. Prim., 2016, 216072

[103] Morris JL, et al. . The CNS theory of osteoarthritis: opportunities beyond the joint. Semin. Arthritis Rheum., 2019, 49: 331-336.

[104] Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res. Ther., 2014, 16: 504

[105] Grassel SG. The role of peripheral nerve fibers and their neurotransmitters in cartilage and bone physiology and pathophysiology. Arthritis Res. Ther., 2014, 16: 485

[106] Lorenz J, et al. . Norepinephrine modulates osteoarthritic chondrocyte metabolism and inflammatory responses. Osteoarthr. Cartil., 2016, 24: 325-334.

[107] El BK, Zaucke F, Meurer A, Straub RH, Jenei-Lanzl Z. Norepinephrine inhibits synovial adipose stem cell chondrogenesis via alpha2a-adrenoceptor-mediated erk1/2 activation. Int. J. Mol. Sci., 2019, 20: 3127.

[108] Jenei-Lanzl Z, et al. . Norepinephrine inhibition of mesenchymal stem cell and chondrogenic progenitor cell chondrogenesis and acceleration of chondrogenic hypertrophy. Arthritis Rheumatol., 2014, 66: 2472-2481.

[109] Suri S, et al. . Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann. Rheum. Dis., 2007, 66: 1423-1428.

[110] Wang Z, Liu B, Lin K, Duan C, Wang C. The presence and degradation of nerve fibers in articular cartilage of neonatal rats. J. Orthop. Surg. Res., 2022, 17: 331

[111] Buljevic S, et al. . Levels of dipeptidyl peptidase IV/cd26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. Rheumatol. Int., 2013, 33: 2867-2874.

[112] Wang L, et al. . Levels of neuropeptide Y in synovial fluid relate to pain in patients with knee osteoarthritis. BMC Musculoskelet. Disord., 2014, 15319

[113] Kang X, et al. . Neuropeptide Y promotes mTORC1 to regulate chondrocyte proliferation and hypertrophy. Endocrinology, 2023, 164: bqac213

[114] Pearson MJ, et al. . IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci. Rep., 2017, 73451

[115] Yang WH, et al. . Leptin induces IL-6 expression through Obrl receptor signaling pathway in human synovial fibroblasts. PLoS One, 2013, 8: e75551

[116] Tong KM, et al. . Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, AKT cascade, and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell Signal., 2008, 20: 1478-1488.

[117] Liu Z, et al. . Novel perspectives on leptin in osteoarthritis: focus on aging. Genes Dis., 2024, 11101159

[118] Zhao X, et al. . Activation of the leptin pathway by high expression of the long form of the leptin receptor (ob-rb) accelerates chondrocyte senescence in osteoarthritis. Bone Jt. Res., 2019, 8: 425-436.

[119] Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet, 2023, 402: 2019-2033.

[120] Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J. Autoimmun., 2020, 110102400

[121] van Delft M, Huizinga T. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun., 2020, 110102392

[122] Neumann E, Lefevre S, Zimmermann B, Gay S, Muller-Ladner U. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol. Med., 2010, 16: 458-468.

[123] Zhang Y, He X, Yin D, Zhang Y. Redefinition of synovial fibroblasts in rheumatoid arthritis. Aging Dis, 2024, 16: 2054-2072.

[124] Jenei-Lanzl Z, et al. . Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis. Ann. Rheum. Dis., 2015, 74: 444-451.

[125] Capellino S, et al. . Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann. Rheum. Dis., 2010, 69: 1853-1860.

[126] Miller LE, Justen HP, Schölmerich J, Straub RH. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J., 2000, 14: 2097-2107.

[127] Nakano K, et al. . Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist sch-23390 inhibits cartilage destruction in a human rheumatoid arthritis/scid mouse chimera model. J. Immunol., 2011, 186: 3745-3752.

[128] van Nie L, et al. . Dopamine induces in vitro migration of synovial fibroblast from patients with rheumatoid arthritis. Sci. Rep., 2020, 1011928

[129] Capellino S, et al. . Increased expression of dopamine receptors in synovial fibroblasts from patients with rheumatoid arthritis: inhibitory effects of dopamine on interleukin-8 and Interleukin-6. Arthritis Rheumatol., 2014, 66: 2685-2693.

[130] Nakashioya H, et al. . Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod. Rheumatol., 2011, 21: 260-266.

[131] Lu JH, Liu YQ, Deng QW, Peng YP, Qiu YH. Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice. Biomed. Res. Int., 2015, 2015496759

[132] Schwendich E, et al. . Modulation of dopamine receptors on osteoblasts as a possible therapeutic strategy for inducing bone formation in arthritis. Cells, 2022, 11: 1609

[133] Mirzaeipoueinak M, et al. . Structure-function characterization of the transition zone in the intervertebral disc. Acta Biomater., 2023, 160: 164-175.

[134] Wu Y, et al. . Brachyury positively regulates extracellular matrix synthesis via directly promoting aggrecan transcription in nucleus pulposus. FASEB J., 2023, 37e22976

[135] Hu X, et al. . Single-cell sequencing: new insights for intervertebral disc degeneration. Biomed. Pharmacother., 2023, 165115224

[136] Sun K, et al. . The role of nerve fibers and their neurotransmitters in regulating intervertebral disc degeneration. Ageing Res. Rev., 2022, 81101733

[137] Zhao Q, et al. . The anatomical study and clinical significance of the sinuvertebral nerves at the lumbar levels. Spine, 2020, 45: E61-E66.

[138] Quinones S, et al. . Clinical anatomy of the lumbar sinuvertebral nerve with regard to discogenic low back pain and review of literature. Eur. Spine J., 2021, 30: 2999-3008.

[139] Barczewska M, Juranek J, Wojtkiewicz J. Origins and neurochemical characteristics of porcine intervertebral disc sympathetic innervation: a preliminary report. J. Mol. Neurosci., 2017, 63: 50-57.

[140] Brenneis M, et al. . Correlation between adrenoceptor expression and clinical parameters in degenerated lumbar intervertebral discs. Int. J. Mol. Sci., 2022, 23: 15358

[141] Rustenburg C, et al. . Osteoarthritis and intervertebral disc degeneration: quite different, quite similar. JOR Spine, 2018, 1e1033

[142] Kupka J, et al. . Adrenoceptor expression during intervertebral disc degeneration. Int. J. Mol. Sci., 2020, 21: 2085

[143] Li F, et al. . Neuropeptide Y and receptors are associated with the pyroptosis of nucleus pulposus in aging and degenerative intervertebral discs of rats. Neuropeptides, 2022, 96102284

[144] Dombrowski ME, et al. . Rabbit annulus fibrosus cells express neuropeptide Y, which is influenced by mechanical and inflammatory stress. Neurospine, 2020, 17: 69-76.

[145] Sun K, et al. . Neuropeptide Y prevents nucleus pulposus cells from cell apoptosis and IL-1beta-induced extracellular matrix degradation. Cell Cycle, 2021, 20: 960-977.

[146] Sun K, et al. . Cgrp regulates nucleus pulposus cell apoptosis and inflammation via the MAPK/nf-kappab signaling pathways during intervertebral disc degeneration. Oxid. Med. Cell Longev., 2021, 20212958584

[147] Huang J, et al. . Beta-receptor blocker enhances the anabolic effect of PTH after osteoporotic fracture. Bone Res., 2024, 12: 18

[148] Yin Z, et al. . Injectable hyperbranched peg crosslinked hyaluronan hydrogel microparticles containing mir-99a-3p modified subcutaneous adscs-derived exosomes were beneficial for long-term treatment of osteoarthritis. Mater. Today Bio., 2023, 23100813

[149] Ousingsawat J, et al. . Airway delivery of hydrogel-encapsulated niclosamide for the treatment of Inflammatory airway disease. Int. J. Mol. Sci., 2022, 23: 1085

[150] Chen Z, et al. . Neuropeptide Y-mediated gut microbiota alterations aggravate postmenopausal osteoporosis. Adv. Sci., 2023, 10e2303015

[151] Collins KH, Guilak F. Trimming the fat - is leptin crosstalk the link between obesity and osteoarthritis?. Osteoarthr. Cartil., 2023, 31: 23-25.

[152] Chen W, et al. . Electroacupuncture activated local sympathetic noradrenergic signaling to relieve synovitis and referred pain behaviors in knee osteoarthritis rats. Front. Mol. Neurosci., 2023, 161069965

[153] Zhou P, He F, Liu B, Wei S. Nerve electrical stimulation enhances osseointegration of implants in the beagle. Sci. Rep., 2019, 94916

[154] Li A, Li Z, Liang Y, He Y, Jiang X. Optimized piezoelectric bone regeneration through inhibiting sympathetic nerve-bone interaction. Surf. Interfaces, 2024, 48: 9

[155] Qiao W, et al. . Divalent metal cations stimulate skeleton interoception for new bone formation in mouse injury models. Nat. Commun., 2022, 13535

[156] Li J, Lou S, Bian X. Osteocalcin and GPR158: linking bone and brain function. Front. Cell Dev. Biol., 2025, 131564751

[157] Zhang H, et al. . Polyhedron-like biomaterials for innervated and vascularized bone regeneration. Adv. Mater., 2023, 35e2302716

[158] Yu J, et al. . Bone-brain interaction: mechanisms and potential intervention strategies of biomaterials. Bone Res., 2025, 13: 38

[159] Sun W, et al. . Neuro-bone tissue engineering: emerging mechanisms, potential strategies, and current challenges. Bone Res., 2023, 11: 65

RIGHTS & PERMISSIONS

The Author(s)